Results 41 to 50 of about 475,202 (310)
Antibodies, 2017 Premature, accelerated onset of atherothrombotic disease is prevalent in patients with systemic lupus erythematosus (SLE). Most, if not all, atherothrombotic diseases are likely to involve platelets and complement.
Chau-Ching Liu +4 more
doaj +1 more source
Kidney International, 1997 Contains fulltext : 24337___.PDF (Publisher’s version ) (Open Access)
openaire +3 more sources
Arthritis Care &Research, EarlyView.Objective We evaluated the ability of the Renal Activity Index for Lupus (RAIL) to discriminate active lupus nephritis (LN) in adult patients with active systemic lupus erythematosus (SLE) and differentiate LN treatment response. Methods Urine samples from adults with biopsy‐proven active class III and IV LN from TULIP‐LN (active LN group ...
Hermine I. Brunner +12 more
wiley +1 more source
Research priorities in childhood-onset lupus: results of a multidisciplinary prioritization exercise
Pediatric Rheumatology Online Journal, 2019 Background Childhood-onset systemic erythematosus lupus (cSLE) is characterized by more severe disease, widespread organ involvement and higher mortality compared to adult-onset SLE. However, cSLE is largely underfunded to carry out necessary research to
Stacy P. Ardoin +11 more
doaj +1 more source
Arthritis Care &Research, EarlyView.Objective A patient‐centered approach for chronic disease management, including systemic lupus erythematosus (SLE), aligns treatment with patients’ values and preferences, leading to improved outcomes. This paper summarizes how patient experiences, perspectives, and priorities informed the American College of Rheumatology (ACR) 2024 Lupus Nephritis (LN)
Shivani Garg +20 more
wiley +1 more source
Arthritis Care &Research, EarlyView.Objective This study aimed to characterize the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of subcutaneous belimumab in pediatric patients with active systemic lupus erythematosus (SLE) receiving standard therapy. Methods This single‐arm, multicenter, open‐label trial (GSK study 200908; ClinicalTrials.gov identifier ...
Hermine I. Brunner +14 more
wiley +1 more source
Arthritis Care &Research, EarlyView.Objective We evaluated the role of 25‐hydroxyvitamin D (25[OH]D), prednisone, and other risk factors for bone mineral density (BMD) loss and osteoporosis in systemic lupus erythematosus (SLE). Methods We calculated the association between 25(OH)D levels and other potential risk factors and BMD measures (spine T scores) and osteoporosis (defined as a T ...
Nima Madanchi +4 more
wiley +1 more source
ACR Open Rheumatology, 2023 Objective To assess outcomes related to Lupus Therapeutics’ Patient Advocates for Lupus Studies (LT‐PALS), a peer‐to‐peer lupus clinical trial (LCT) education program designed to improve representation of diverse groups in LCTs.
Saira Z. Sheikh +12 more
doaj +1 more source
Systemic 5-fluorouracil induced lupus erythematosus: a review of the literature [PDF]
, 2019 Drug-induced subacute cutaneous lupus erythematosus (SCLE) is the most common subtype of drug-induced systemic lupus erythematosus and has been associated with more than 100 drugs.
Marsch, Amanda F, Shakhbazova, Anastasia
core
Vitamin D supplementation in systemic lupus erythematosus patients with vitamin D deficiency and insufficiency : the effect on disease activity, fatigue and interferon signature gene expression [PDF]
, 2019 Background: Vitamin D deficiency is highly prevalent among patients with systemic lupus erythematosus (SLE) [1]. Evidence from multiple studies has shown that vitamin D deficiency in SLE is associated with a higher disease activity [2].
Borg, Andrew +4 more
core +1 more source